Clinical Trials Browser

Disease × ibrutinib × Other hematologic neoplasm × Clear all

NCT03755947 2021-02-02

Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia

Phase 2 Completed

LymphoidOther hematologic neoplasm

Disease, Leukemia, Lymphocytic, Chronic, B-Cell